Skip to main content
    Paid monthly and annual subscribers can read every Medi-Chi book online — including clinical references and the TCM Textbook · downloads sold separatelySee the libraryClinical Education Tool — This platform provides educational resources for TCM practitioners and students. It does not issue medical certificates, prescriptions, or clinical diagnoses.
    dermatology

    Stevens–Johnson syndrome and toxic epidermal necrolysis

    Also known as: Stevens–Johnson syndrome, toxic epidermal necrolysis, SJS/TEN spectrum, SJS–TEN overlap

    Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe, life-threatening mucocutaneous reactions characterised by painful erythema, bullae formation, and extensive epidermal detachment. These conditions frequently result from adverse drug reactions. Suspected cases necessitate immediate hospitalisation for emergency stabilization, identifies and cessation of the causative agent, and multidisciplinary management. The cited evidence, comprising retrospective studies and case reports, evaluates mortality rates, sepsis risks, and immunotherapy-related reactions; it does not establish the efficacy of acupuncture or Chinese herbal medicine for these conditions. Traditional Chinese Medicine (TCM) must not be employed for acute emergency management or to delay medical referral. Adjunctive TCM for recovery-phase sequelae should only be initiated following specialist clearance once the patient is medically stable. Recovery patterns denote traditional frameworks rather than validated therapeutic interventions and must not substitute for specialist dermatological, ophthalmological, or oncological follow-up.

    Plain-English one-pager you can print or hand to a patient. Free, no sign-in needed.

    All clinical details on this page are for practitioner premium subscribers only.
    Checking your practitioner access
    Verifying your Medi-Chi access…

    Lifestyle & Diet

    • •Maintain a comprehensive and current record of pharmacological allergies; disseminate the specialist-confirmed list of causative agents to all medical and pharmaceutical providers.
    • •Utilise exclusively medical-team-approved topical dermatological, ocular, and oral agents; avoid unverified supplements and fragranced products during the recovery phase.
    • •Adhere to physician-prescribed hydration and nutritional protocols; request dietetic consultation if oropharyngeal lesions impact nutritional intake.
    • •Implement a gradual return to physical activity and ensure strict adherence to longitudinal follow-up schedules with dermatology and ophthalmology specialists.

    Cautions & Contraindications

    See sources
    • •Suspected or active SJS/TEN excludes acupuncture, moxibustion, cupping, scraping and herbal treatment: prioritise emergency referral and prompt medical withdrawal of suspected culprit medicines.[,]
    • •Never intentionally rechallenge a suspected culprit medicine or supplement. Obtain specialist causality advice before considering any new herbal product; multiple ingredients complicate adverse-reaction assessment.[]
    • •Do not needle blistered, eroded, infected, fragile or incompletely healed skin. Defer elective needling during systemic illness or unresolved infection risk; skin loss and septic shock are serious features of this condition.[]
    • •Do not use complementary care to delay assessment of a new rash during cancer immunotherapy, or independently alter oncology treatment. Contact the oncology team and arrange urgent assessment.[,]

    When to reassess or seek care again

    See sources

    Acute suspicion requires immediate referral, not a trial of treatment. After complete stabilisation and specialist clearance, review any adjunctive recovery plan within 1–2 weeks using fatigue and sleep scores, appetite, oral intake, weight trend and functional activity. Stop adjunctive care and obtain urgent assessment for new rash, fever, mucosal injury, eye symptoms or systemic deterioration. Refer persistent weight loss, poor intake or worsening fatigue to the treating team; discontinue an ineffective adjunctive trial rather than escalating empirically.

    Explore more diseases

    Sources & Further Reading

    Clinical guidance, red flags and safety notes on this page draw on the following current sources alongside the classical references above.

    1. Indian dermatology online journal · 2026
    2. Cutaneous and ocular toxicology · 2026
    3. Frontiers in pediatrics · 2026
    4. Investigational new drugs · 2025
    5. Cochrane Database of Systematic Reviews · 2015

      Systematic review supporting PC6 stimulation for postoperative nausea and vomiting.

    6. JAMA Surgery · 2023

      Randomised trial including ST36 for postoperative gastrointestinal recovery.

    7. Medical Journal of Australia · 2017

      Australian emergency-department trial of acupuncture used alongside standard analgesic care.

    8. World Health Organization · 2008

      Standard point locations used for the adjunctive points listed.

    Educational reference for licensed practitioners. Not a substitute for individual clinical assessment. Refer to conventional care for any red-flag or undiagnosed presentation.